Vanderperre, Benoît https://orcid.org/0000-0002-2111-1071
Muraleedharan, Amitha
Dorion, Marie-France https://orcid.org/0000-0003-1285-6087
Larroquette, Frédérique
Del Cid Pellitero, Esther https://orcid.org/0000-0001-8658-944X
Rajakulendran, Nishani
Chen, Carol X.-Q.
Larivière, Roxanne
Michaud-Tardif, Charlotte
Goiran, Thomas
Chidiac, Rony
Lipuma, Damien
MacLeod, Graham
Thomas, Rhalena https://orcid.org/0000-0002-5396-7587
Wang, Zhangjie
Reintsch, Wolfgang E.
Luo, Wen https://orcid.org/0000-0003-1785-9615
Shlaifer, Irina https://orcid.org/0000-0002-3737-268X
Zhang, Fuming https://orcid.org/0000-0003-2803-3704
Xia, Ke
Steinhart, Zachary
Linhardt, Robert J. https://orcid.org/0000-0003-2219-5833
Trempe, Jean-François https://orcid.org/0000-0002-6543-3371
Liu, Jian
Durcan, Thomas M.
Angers, Stephane https://orcid.org/0000-0001-7241-9044
Fon, Edward A. https://orcid.org/0000-0002-5520-6239
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (021129)
Gouvernement du Canada | Canadian Institutes of Health Research (MFE-152571, Canada Research Chair (Tier 1) in Parkinson’s disease)
Canada First Research Excellence Fund, Healthy Brain, Healthy Lives awarded to McGill University
PROTEO
Article History
Received: 24 December 2024
Accepted: 22 August 2025
First Online: 6 October 2025
Competing interests
: J.L. is a founder and chief scientific officer of Glycan Therapeutics Corp. Z.W. is currently an employee of Glycan Therapeutics Corp. Other authors have no competing interest to declare.